[go: up one dir, main page]

EP0773716A4 - Traitement de solutions de globules rouges par des agents antiviraux - Google Patents

Traitement de solutions de globules rouges par des agents antiviraux

Info

Publication number
EP0773716A4
EP0773716A4 EP96918369A EP96918369A EP0773716A4 EP 0773716 A4 EP0773716 A4 EP 0773716A4 EP 96918369 A EP96918369 A EP 96918369A EP 96918369 A EP96918369 A EP 96918369A EP 0773716 A4 EP0773716 A4 EP 0773716A4
Authority
EP
European Patent Office
Prior art keywords
red blood
blood cell
viral agents
cell solutions
treating red
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96918369A
Other languages
German (de)
English (en)
Other versions
EP0773716A1 (fr
Inventor
David Cook
Susan Wollowitz
Aileen Nerio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/476,842 external-priority patent/US6143490A/en
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of EP0773716A1 publication Critical patent/EP0773716A1/fr
Publication of EP0773716A4 publication Critical patent/EP0773716A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96918369A 1995-06-07 1996-06-07 Traitement de solutions de globules rouges par des agents antiviraux Withdrawn EP0773716A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/476,842 US6143490A (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
US476842 1995-06-07
US08/486,821 US6171777B1 (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
US486821 1995-06-07
PCT/US1996/009616 WO1996039818A1 (fr) 1995-06-07 1996-06-07 Traitement de solutions de globules rouges par des agents antiviraux

Publications (2)

Publication Number Publication Date
EP0773716A1 EP0773716A1 (fr) 1997-05-21
EP0773716A4 true EP0773716A4 (fr) 1999-08-04

Family

ID=27045311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96918369A Withdrawn EP0773716A4 (fr) 1995-06-07 1996-06-07 Traitement de solutions de globules rouges par des agents antiviraux

Country Status (4)

Country Link
EP (1) EP0773716A4 (fr)
AU (1) AU722811B2 (fr)
CA (1) CA2199731A1 (fr)
WO (1) WO1996039818A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US20010018179A1 (en) 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
WO1998030327A1 (fr) * 1997-01-06 1998-07-16 Cerus Corporation Procedes et dispositifs permettant de reduire de petits composes organiques presents dans des produits sanguins
US20010009756A1 (en) 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
EP1364944A1 (fr) * 1997-01-06 2003-11-26 Cerus Corporation Composés frangibles pour inactivation pathogène
CN101676268B (zh) * 1997-01-06 2013-09-25 塞鲁斯公司 用于病原体灭活的脆性化合物
AU773836B2 (en) * 1997-01-06 2004-06-10 Cerus Corporation Methods and devices for the reduction of small organic compounds from blood products
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6352695B1 (en) 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
CA2317430A1 (fr) * 1998-01-06 1999-07-15 Cerus Corporation Dispositifs d'ecoulement permettant de reduire la concentration de composes dans des compositions biologiques et procedes associes
WO1999034839A1 (fr) * 1998-01-06 1999-07-15 Cerus Corporation Procedes permettant d'inhiber les inactivateurs de pathogenes dans des matieres biologiques
US7611831B2 (en) 1998-01-06 2009-11-03 Cerus Corporation Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
CA2332314A1 (fr) 1998-06-11 1999-12-16 Cerus Corporation Inhibition de la proliferation des cellules musculaires lisses arterielles
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
JP4839209B2 (ja) 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
DK1592441T3 (da) 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
JP2007512341A (ja) * 2003-11-21 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド 神経障害性疼痛の治療に有用なピリジン−４−イルアミン化合物
PT1838355E (pt) 2004-10-29 2013-11-07 Cerus Corp Métodos de inibição melhorados destinados a um processo de inativação de glóbulos vermelhos
EA023596B1 (ru) 2008-04-09 2016-06-30 Сирус Корпорейшн Способы обработки композиции эритроцитов для инактивации патогена
CN101857598B (zh) * 2010-06-25 2012-11-28 西安交通大学 一种具有降高血压活性的呋喃香豆素类化合物及其制备方法
WO2012154879A2 (fr) 2011-05-09 2012-11-15 Van Andel Research Institute Inhibiteurs d'autophagie
EA201890149A1 (ru) 2015-06-26 2018-07-31 Сирус Корпорейшн Композиции криопреципитатов и способы их получения
ES2972443T3 (es) 2015-10-23 2024-06-12 Cerus Corp Plasma pobre en crioprecipitado inactivado para patógenos y métodos de uso del mismo
AU2017382449B2 (en) 2016-12-23 2024-10-24 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
EP3589297A1 (fr) 2017-03-03 2020-01-08 Cerus Corporation Kits et méthodes de préparation de compositions de plaquettes inactivées par des agents pathogènes
CN111770789B (zh) 2017-12-29 2023-05-05 塞鲁斯公司 用于处理生物流体的系统和方法
CA3143213A1 (fr) 2019-06-22 2020-12-30 Cerus Corporation Systemes de traitement de fluides biologiques
EP3991179A1 (fr) 2019-06-28 2022-05-04 Cerus Corporation Système et procédés permettant de mettre en oeuvre un dispositif de traitement de fluide biologique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (fr) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. Système de traitement du sang en dehors du corps
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182750A (en) * 1977-04-21 1980-01-08 Sullivan Thomas E Bloodcompatible functional polymers
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
ATE451445T1 (de) * 1995-06-07 2009-12-15 Cerus Corp Verfahren und vorrichtungen zur entfernung von psoralenen aus blutprodukten.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (fr) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. Système de traitement du sang en dehors du corps
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RYTIR V ET AL: "Effect of certain compounds during elimination of plasmids in Escherichia coli", FOLIA MICROBIOLOGICA, vol. 20, no. 1, 1975, Prague, Czech., pages 17 - 23, XP002101363 *
See also references of WO9639818A1 *

Also Published As

Publication number Publication date
CA2199731A1 (fr) 1996-12-19
EP0773716A1 (fr) 1997-05-21
AU722811B2 (en) 2000-08-10
AU6104996A (en) 1996-12-30
WO1996039818A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
EP0773716A4 (fr) Traitement de solutions de globules rouges par des agents antiviraux
GB2276639B (en) Solutions for wood treatment and their preparation
GB2287879B (en) Baths
IL111477A0 (en) Stable lycopene concentrates and process for their preparation
AU2361695A (en) Red blood cell surrogate
GB2236939B (en) Underpants with smooth sides
BR9305166A (pt) Aperfeiçoamentos introduzidos em oxigenador de sangue
GB2289339B (en) Flow-through electrochemical biosensor
SG48549A1 (en) Diffusion cell
GB9512529D0 (en) Cell treatment
ZA968943B (en) Ophthalmic solution
EP0737368A4 (fr) Systeme de circulation de l'electrolyte dans une batterie
AUPM424894A0 (en) Treatment of electrolyte solutions
GB9507845D0 (en) Improvements in or relating to the handling of solutions
GB9305850D0 (en) Improvements in or relating to baths
IL118381A0 (en) Solutions containing erythromycylamine and their use
ZA959995B (en) Lubeluzole intravenous solutions
AU6524094A (en) Blood oxygenating system with improved safety features
GB8919880D0 (en) Treating red blood cells
GB9506178D0 (en) Cell concentration
GB9500585D0 (en) Improvements in baths
GB8820909D0 (en) Treating red blood cells
GB9314902D0 (en) Improvements in anti-viral therapy
AU1885595A (en) Treatement of electrolyte solutions
BR7401305U (pt) Aperfeiçoamento em cateter de oxigenação

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19970304

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61L 2/00 A, 6A 61L 2/18 B

A4 Supplementary search report drawn up and despatched

Effective date: 19990621

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CERUS CORPORATION

17Q First examination report despatched

Effective date: 20010319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001